Thrombospondin-1: The good, the bad, and the complicated

Circulation Research

Volumn 113, Issue 12, 2013, Pages 1272-1274

  Ma, Yonggang ^a   Yabluchanskiy, Andriy ^a   Lindsey, Merry L ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b G V SONNY MONTGOMERY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

diabetic cardiomyopathies; Editorial; matrix metalloproteinase 9; proteomics; thrombospondin 1

Indexed keywords

ANGIOPOIETIN 2; CHEMOKINE; COLLAGEN; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; SMAD2 PROTEIN; SMAD3 PROTEIN; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CELL MIGRATION; COLLAGEN SYNTHESIS; CYTOKINE RELEASE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISEASE PREDISPOSITION; EDITORIAL; ENDOTHELIUM CELL; ENZYME ACTIVATION; HEART; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INSULIN SENSITIVITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; WEIGHT GAIN;

DIABETIC CARDIOMYOPATHIES; EDITORIAL; MATRIX METALLOPRO TEINASE 9; PROTEOMICS; THROMBOSPONDIN 1;

ANGIOPOIETIN-2; ANIMALS; DIABETES MELLITUS; FEMALE; MALE; MYOCARDIUM; THROMBOSPONDIN 1; UP-REGULATION; VENTRICULAR REMODELING;

EID: 84890321587     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.113.302749     Document Type: Editorial

References (23)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40
2. Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy: Pathophysiology and clinical features. Heart Fail Rev. 2013;18:149-166
3. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: Insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121:748-757
4. Ma Y, Halade GV, Lindsey ML. Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res. 2012;5:848-857
5. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev. 2012;92:635-688
6. Gonzalez-Quesada C, Cavalera M, Biernacka A, Kong P, Lee DW, Saxena A, Frunza O, Dobaczewski M, Shinde A, Frangogiannis NG. Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. Circ Res. 2013;113:1331-1344
7. Falcão-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: Understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev. 2012;17:325-344
8. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860-867
9. Wen HL, Liang ZS, Zhang R, Yang K. Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy. Cardiovasc Diabetol. 2013;12:50
10. Zhao Y, Zhang L, Qiao Y, et al. Heme oxygenase-1 prevents cardiac dysfunction in streptozotocin-diabetic mice by reducing inflammation, oxidative stress, apoptosis and enhancing autophagy. PLoS One. 2013;8:e75927
11. Lan HY. Transforming growth factor-β/Smad signalling in diabetic nephropathy. Clin Exp Pharmacol Physiol. 2012;39:731-738
12. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem. 1994;269:26775-26782
13. Factor SM, Minase T, Sonnenblick EH. Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am Heart J. 1980;99:446-458
14. Factor SM, Minase T, Cho S, Fein F, Capasso JM, Sonnenblick EH. Coronary microvascular abnormalities in the hypertensive-diabetic rat. A primary cause of cardiomyopathy? Am J Pathol. 1984;116:9-20
15. Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med. 2012;2:a006627
16. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD. Regulation of nitric oxide signalling by thrombospondin 1: Implications for antiangiogenic therapies. Nat Rev Cancer. 2009;9:182-194
17. Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Angiopoietin-2: An attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013;73:1649-1657
18. Roth JJ, Gahtan V, Brown JL, Gerhard C, Swami VK, Rothman VL, Tulenko TN, Tuszynski GP. Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. J Surg Res. 1998;74:11-16
19. de Castro Brás LE, Ramirez TA, DeLeon-Pennell KY, Chiao YA, Ma Y, Dai Q, Halade GV, Hakala K, Weintraub ST, Lindsey ML. Texas 3-step decellularization protocol: Looking at the cardiac extracellular matrix. J Proteomics. 2013;86:43-52
20. Yabluchanskiy A, Li Y, Chilton RJ, Lindsey ML. Matrix metalloproteinases: Drug targets for myocardial infarction. Curr Drug Targets. 2013;14:276-286
21. Li Y, Tong X, Rumala C, Clemons K, Wang S. Thrombospondin1 deficiency reduces obesity-Associated inflammation and improves insulin sensitivity in a diet-induced obese mouse model. PLoS One. 2011;6:e26656
22. Frangogiannis NG, Ren G, Dewald O, Zymek P, Haudek S, Koerting A, Winkelmann K, Michael LH, Lawler J, Entman ML. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation. 2005;111:2935-2942
23. Xia Y, Dobaczewski M, Gonzalez-Quesada C, Chen W, Biernacka A, Li N, Lee DW, Frangogiannis NG. Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension. 2011;58:902-911